German pharmaceutical company Merck KgaA says a late stage trial of a new lung cancer drug has failed to meet expectations. The company, based in Darmstadt, says the drug Stimuvax did not improve the overall survival of patients in the phase III study.
FULL ARTICLE AT Virginian-Pilot Online
1 of 2
Merck KGaA had said that phase III clinical trials of Erbitux for treatment of gastric cancer drug had shown no benefits
An experimental lung cancer vaccine from Germany's Merck KGaA failed to improve survival in a pivotal study, dealing a blow to the company and the high-risk field of using vaccines to fight tumors. Stimuvax, which Merck licensed from U.S. biotech...